ClinicalTrials.gg

Program

BTK Inhibitor TQB3702

Also written as “TQB3702 tablets” and “TQB3702 Tablets”.

In Sino Biopharmaceutical’s pipeline, BTK抑制剂. Its studies are mostly in Lupus Erythematosus, Systemic · Hematologic Neoplasms, led by Sino Biopharmaceutical.

Furthest: phase 2, since Feb 27, 20254 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Sino Biopharmaceutical43 open or runningphase 2since Feb 27, 2025Nov 2, 2022Dec 2026phase 2 · NCT06859931

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Nov 2, 2022First study: phase 1 study in Hematologic NeoplasmsFirst studyNCT05610202 · 137 enrolled · China
  2. Jan 9, 2024Phase 1 study in Hematologic NeoplasmsNCT06211751 · 208 planned · China
  3. Jun 4, 2024Phase 1 study in Lupus Erythematosus, SystemicNCT06448273 · 40 planned · China
  4. Feb 27, 2025Phase 2 study in Lupus Erythematosus, SystemicNCT06859931 · 120 planned · China

Ahead

  1. Dec 2026Primary completion: phase 2 study in Lupus Erythematosus, SystemicNCT06859931

TargetBeta

“BTK抑制剂”the company's pipeline, read by Claude · source
“An orally bioavailable inhibitor of Bruton's tyrosine kinase (BTK; Bruton agammaglobulinemia tyrosine kinase), ”NCIt, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
tirabrutinibruleGilead Sciencesphase 313

Studies

All 4 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06859931Lupus Erythematosus, Systemic · China2Not yet recruitingDec 2026120
NCT06448273Lupus Erythematosus, Systemic · China1RecruitingOct 202440
NCT06211751Hematologic Neoplasms · China1Not yet recruitingDec 2025208
NCT05610202Hematologic Neoplasms · China1UNKNOWNAug 2024137

How it is read

Names in the registry

  • “TQB3702 tablets”, 3 entries
  • “TQB3702 Tablets”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.